

Andreas GÃ¼nther

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3442589/publications.pdf>

Version: 2024-02-01

91
papers

5,791
citations

101535

36
h-index

79691

73
g-index

98
all docs

98
docs citations

98
times ranked

7965
citing authors

#	ARTICLE	IF	CITATIONS
1	Myeloid-cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice. <i>European Respiratory Journal</i> , 2022, 59, 2101153.	6.7	13
2	Differential LysoTracker Uptake Defines Two Populations of Distal Epithelial Cells in Idiopathic Pulmonary Fibrosis. <i>Cells</i> , 2022, 11, 235.	4.1	6
3	Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival. <i>Circulation Research</i> , 2022, 130, 760-778.	4.5	19
4	PACS2â€“TRPV1 axis is required for ERâ€“mitochondrial tethering during ER stress and lung fibrosis. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 151.	5.4	9
5	Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option. <i>Cells</i> , 2022, 11, 1626.	4.1	22
6	Cell-Surface Programmed Death Ligand-1 Expression Identifies a Sub-Population of Distal Epithelial Cells Enriched in Idiopathic Pulmonary Fibrosis. <i>Cells</i> , 2022, 11, 1593.	4.1	11
7	Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	15
8	Transcriptional Profiling of Insulin-like Growth Factor Signaling Components in Embryonic Lung Development and Idiopathic Pulmonary Fibrosis. <i>Cells</i> , 2022, 11, 1973.	4.1	4
9	Defective BACH1/HO-1 regulatory circuits in cystic fibrosis bronchial epithelial cells. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 140-148.	0.7	10
10	Evaluation of Regional Pulmonary Ventilation in Spontaneously Breathing Patients with Idiopathic Pulmonary Fibrosis (IPF) Employing Electrical Impedance Tomography (EIT): A Pilot Study from the European IPF Registry (eurlPFreg). <i>Journal of Clinical Medicine</i> , 2021, 10, 192.	2.4	7
11	Positioning of nucleosomes containing γ^3 -H2AX precedes active DNA demethylation and transcription initiation. <i>Nature Communications</i> , 2021, 12, 1072.	12.8	30
12	Identification of a novel subset of alveolar type 2 cells enriched in PD-L1 and expanded following pneumonectomy. <i>European Respiratory Journal</i> , 2021, 58, 2004168.	6.7	31
13	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 476-486.	10.7	254
14	Adenylate Kinase 4â€“A Key Regulator of Proliferation and Metabolic Shift in Human Pulmonary Arterial Smooth Muscle Cells via Akt and HIF-1 α Signaling Pathways. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10371.	4.1	11
15	Small extracellular vesicleâ€“derived miRâ€“574â€“5p regulates PGE2â€“biosynthesis via TLR7/8 in lung cancer. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12143.	12.2	21
16	Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. <i>Cancers</i> , 2021, 13, 208.	3.7	10
17	Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0258684.	2.5	5
18	The Collaborative Metadata Repository (CoMetaR) Web App: Quantitative and Qualitative Usability Evaluation. <i>JMIR Medical Informatics</i> , 2021, 9, e30308.	2.6	2

#	ARTICLE	IF	CITATIONS
19	Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurlPFreg). <i>Journal of Clinical Medicine</i> , 2020, 9, 3763.	2.4	11
20	A FOX-like Mechanism Regulating Lung Fibroblasts: Are We Getting There?. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 63, 723-724.	2.9	1
21	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. <i>Nature Metabolism</i> , 2020, 2, 532-546.	11.9	23
22	Long Noncoding RNA TYKRIL Plays a Role in Pulmonary Hypertension via the p53-mediated Regulation of PDGFR β . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1445-1457.	5.6	45
23	Chemosensory Cell-Derived Acetylcholine Drives Tracheal Mucociliary Clearance in Response to Virulence-Associated Formyl Peptides. <i>Immunity</i> , 2020, 52, 683-699.e11.	14.3	63
24	Multilineage murine stem cells generate complex organoids to model distal lung development and disease. <i>EMBO Journal</i> , 2020, 39, e103476.	7.8	44
25	Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF). <i>BMC Pulmonary Medicine</i> , 2019, 19, 130.	2.0	32
26	Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. <i>Nature Communications</i> , 2019, 10, 2987.	12.8	181
27	Proteasome activator PA200 regulates myofibroblast differentiation. <i>Scientific Reports</i> , 2019, 9, 15224.	3.3	14
28	Exploring the Ability of Electronic Nose Technology to Recognize Interstitial Lung Diseases (ILD) by Non-Invasive Breath Screening of Exhaled Volatile Compounds (VOC): A Pilot Study from the European IPF Registry (eurlPFreg) and Biobank. <i>Journal of Clinical Medicine</i> , 2019, 8, 1698.	2.4	20
29	The Oncogene ECT2 Contributes to a Hyperplastic, Proliferative Lung Epithelial Cell Phenotype in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 61, 713-726.	2.9	15
30	Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis. <i>Nature Communications</i> , 2019, 10, 2229.	12.8	53
31	Exhalative Breath Markers Do Not Offer for Diagnosis of Interstitial Lung Diseases: Data from the European IPF Registry (eurlPFreg) and Biobank. <i>Journal of Clinical Medicine</i> , 2019, 8, 643.	2.4	9
32	Regulation and role of the ER stress transcription factor CHOP in alveolar epithelial type-II cells. <i>Journal of Molecular Medicine</i> , 2019, 97, 973-990.	3.9	31
33	Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis. <i>Respiratory Research</i> , 2019, 20, 47.	3.6	31
34	Lung CT Densitometry in Idiopathic Pulmonary Fibrosis for the Prediction of Natural Course, Severity, and Mortality. <i>Chest</i> , 2019, 155, 972-981.	0.8	32
35	WNT/RYK signaling restricts goblet cell differentiation during lung development and repair. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 25697-25706.	7.1	35
36	Verifying Data Integration Configurations for Semantical Correctness and Completeness. <i>Studies in Health Technology and Informatics</i> , 2019, 267, 66-73.	0.3	2

#	ARTICLE	IF	CITATIONS
37	Provenance for Biomedical Ontologies with RDF and Git. <i>Studies in Health Technology and Informatics</i> , 2019, 267, 230-237.	0.3	4
38	Hermansky-Pudlak syndrome type 2 manifests with fibrosing lung disease early in childhood. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 42.	2.7	33
39	Cell-specific expression of runt-related transcription factor 2 contributes to pulmonary fibrosis. <i>FASEB Journal</i> , 2018, 32, 703-716.	0.5	28
40	FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. <i>EMBO Molecular Medicine</i> , 2018, 10, 276-293.	6.9	85
41	Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. <i>PLoS ONE</i> , 2018, 13, e0207915.	2.5	38
42	Myh10 deficiency leads to defective extracellular matrix remodeling and pulmonary disease. <i>Nature Communications</i> , 2018, 9, 4600.	12.8	27
43	The European IPF registry (eurlPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2018, 19, 141.	3.6	199
44	Increased Extracellular Vesicles Mediate WNT5A Signaling in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1527-1538.	5.6	127
45	Using RDF and Git to Realize a Collaborative Metadata Repository. <i>Studies in Health Technology and Informatics</i> , 2018, 247, 556-560.	0.3	1
46	Metadata Import from RDF to i2b2. <i>Studies in Health Technology and Informatics</i> , 2018, 253, 40-44.	0.3	2
47	Noncanonical WNT-5A signaling impairs endogenous lung repair in COPD. <i>Journal of Experimental Medicine</i> , 2017, 214, 143-163.	8.5	122
48	Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis <i>in vivo</i> . <i>European Respiratory Journal</i> , 2017, 50, 1602367.	6.7	267
49	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. <i>Lancet Respiratory Medicine</i> , 2017, 5, 591-598.	10.7	71
50	Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. <i>Cell Stem Cell</i> , 2017, 20, 261-273.e3.	11.1	217
51	Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. <i>BMC Pulmonary Medicine</i> , 2017, 17, 122.	2.0	94
52	Tubastatin ameliorates pulmonary fibrosis by targeting the TGF β ² -PI3K-Akt pathway. <i>PLoS ONE</i> , 2017, 12, e0186615.	2.5	76
53	Non-invasive lung cancer diagnosis by detection of <i>GATA6</i> and <i>NKX2-1</i> isoforms in exhaled breath condensate. <i>EMBO Molecular Medicine</i> , 2016, 8, 1380-1389.	6.9	29
54	The role of Endoplasmic Reticulum (ER) stress in pulmonary fibrosis. <i>Endoplasmic Reticulum Stress in Diseases</i> , 2016, 3, .	0.2	2

#	ARTICLE	IF	CITATIONS
55	MAP1LC3B overexpression protects against Hermansky-Pudlak syndrome type-1-induced defective autophagy in vitro. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016, 310, L519-L531.	2.9	25
56	A small molecule neutrophil elastase inhibitor, KRP-109, inhibits cystic fibrosis mucin degradation. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 325-331.	0.7	11
57	Regulation of Immunoproteasome Function in the Lung. <i>Scientific Reports</i> , 2015, 5, 10230.	3.3	64
58	Regulation of macroautophagy in amiodarone-induced pulmonary fibrosis. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 252-263.	3.0	27
59	Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction. <i>Respiratory Research</i> , 2015, 16, 85.	3.6	23
60	Regulation of 26S Proteasome Activity in Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1089-1101.	5.6	38
61	Linking progression of fibrotic lung remodeling and ultrastructural alterations of alveolar epithelial type II cells in the amiodarone mouse model. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L63-L75.	2.9	29
62	Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. <i>Thorax</i> , 2015, 70, 1022-1032.	5.6	106
63	Forkhead Box F1 represses cell growth and inhibits COL1 and ARPC2 expression in lung fibroblasts in vitro. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 307, L838-L847.	2.9	30
64	Altered Surfactant Homeostasis and Alveolar Epithelial Cell Stress in Amiodarone-Induced Lung Fibrosis. <i>Toxicological Sciences</i> , 2014, 142, 285-297.	3.1	40
65	Impaired TLR4 and HIF expression in cystic fibrosis bronchial epithelial cells downregulates hemeoxygenase-1 and alters iron homeostasis in vitro. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 307, L791-L799.	2.9	32
66	Biophysical inhibition of pulmonary surfactant function by polymeric nanoparticles: Role of surfactant protein B and C. <i>Acta Biomaterialia</i> , 2014, 10, 4678-4684.	8.3	25
67	Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and organ donors. <i>Journal of Proteomics</i> , 2013, 85, 109-128.	2.4	64
68	Pivotal Role of Matrix Metalloproteinase 13 in Extracellular Matrix Turnover in Idiopathic Pulmonary Fibrosis. <i>PLoS ONE</i> , 2013, 8, e73279.	2.5	77
69	Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. <i>European Respiratory Review</i> , 2012, 21, 152-160.	7.1	122
70	Comparative Proteomic Analysis of Lung Tissue from Patients with Idiopathic Pulmonary Fibrosis (IPF) and Lung Transplant Donor Lungs. <i>Journal of Proteome Research</i> , 2011, 10, 2185-2205.	3.7	80
71	Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 341-350.	3.3	97
72	Shedding of Low-Density Lipoprotein Receptor-related Protein-1 in Acute Respiratory Distress Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 438-448.	5.6	36

#	ARTICLE	IF	CITATIONS
73	Ectopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosis. <i>Thorax</i> , 2011, 66, 651-657.	5.6	159
74	The Role of Dimethylarginine Dimethylaminohydrolase in Idiopathic Pulmonary Fibrosis. <i>Science Translational Medicine</i> , 2011, 03, 87ra53.	12.4	59
75	Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. <i>BMC Pulmonary Medicine</i> , 2010, 10, 26.	2.0	38
76	Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2010, 11, 146.	3.6	22
77	Expression and Activity of Phosphodiesterase Isoforms during Epithelial Mesenchymal Transition: The Role of Phosphodiesterase 4. <i>Molecular Biology of the Cell</i> , 2009, 20, 4751-4765.	2.1	84
78	Alveolar Oxidative Stress is Associated with Elevated Levels of Nonenzymatic Low-Molecular-Weight Antioxidants in Patients with Different Forms of Chronic Fibrosing Interstitial Lung Diseases. <i>Antioxidants and Redox Signaling</i> , 2009, 11, 227-240.	5.4	46
79	WNT1-inducible signaling protein 1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. <i>Journal of Clinical Investigation</i> , 2009, 119, 772-87.	8.2	447
80	Epithelial Endoplasmic Reticulum Stress and Apoptosis in Sporadic Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 838-846.	5.6	447
81	Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. <i>Thrombosis and Haemostasis</i> , 2008, 99, 494-501.	3.4	83
82	Raised protein levels and altered cellular expression of factor VII activating protease (FSAP) in the lungs of patients with acute respiratory distress syndrome (ARDS). <i>Thorax</i> , 2007, 62, 880-888.	5.6	30
83	Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. <i>Thorax</i> , 2007, 62, 588-594.	5.6	66
84	Chronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 39-45.	5.6	230
85	Surfactant abnormalities after single lung transplantation in dogs: impact of bronchoscopic surfactant administration. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2004, 127, 344-354.	0.8	30
86	Synthetic and natural surfactant differentially modulate inflammation after meconium aspiration. <i>Intensive Care Medicine</i> , 2003, 29, 2247-2254.	8.2	22
87	Prevention of Bleomycin-induced Lung Fibrosis by Aerosolization of Heparin or Urokinase in Rabbits. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 1358-1365.	5.6	167
88	Surfactant alteration and replacement in acute respiratory distress syndrome. <i>Respiratory Research</i> , 2001, 2, 353.	3.6	199
89	Pulmonary surfactant: functions, abnormalities and therapeutic options. <i>Intensive Care Medicine</i> , 2001, 27, 1699-1717.	8.2	141
90	Pathophysiology of Acute Lung Injury. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2001, 22, 247-258.	2.1	34

#	ARTICLE	IF	CITATIONS
91	Cleavage of Surfactant-Incorporating Fibrin by Different Fibrinolytic Agents. American Journal of Respiratory Cell and Molecular Biology, 1999, 21, 738-745.	2.9	14